Literature DB >> 7044276

Therapy of hyperlipidemic states.

R J Havel, J P Kane.   

Abstract

Mesh:

Substances:

Year:  1982        PMID: 7044276     DOI: 10.1146/annurev.me.33.020182.002221

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


× No keyword cloud information.
  7 in total

Review 1.  The evaluation and treatment of hypercholesterolemia in primary care practice.

Authors:  W L Peters; A H Goroll
Journal:  J Gen Intern Med       Date:  1986 May-Jun       Impact factor: 5.128

2.  Structure activity relationships of imido N-alkyl semicarbazones, thiosemicarbazones and acethydrazones as hypolipidemic agents in rodents.

Authors:  J M Chapman; P DeLucy; O T Wong; I H Hall
Journal:  Lipids       Date:  1990-07       Impact factor: 1.880

Review 3.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

4.  The hypolipidemic activity of 1-N-3-methylphthalimido-butan-3-semicarbazone in rodents.

Authors:  O T Wong; I H Hall; J M Chapman
Journal:  Pharm Res       Date:  1989-03       Impact factor: 4.200

5.  Specific changes in the protein composition of rat liver in response to the peroxisome proliferators ciprofibrate, Wy-14,643 and di-(2-ethylhexyl)phthalate.

Authors:  T Watanabe; N D Lalwani; J K Reddy
Journal:  Biochem J       Date:  1985-05-01       Impact factor: 3.857

6.  Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.

Authors:  D R Illingworth; G J Sexton
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

7.  The effects of phthalimide and saccharin derivatives on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) receptor activity and related enzyme activities.

Authors:  I H Hall; O T Wong; S D Wyrick
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.